Artificial intelligence is rapidly transforming protein engineering and drug development. European Molecular Biology Laboratory researchers introduced AlphaDesign, an AI-driven framework building on AlphaFold for de novo protein design, enabling creation of novel therapeutics with predicted structural and functional accuracy. Insilico Medicine leveraged their Chemistry42 platform to generate new chemotype pan-KRAS inhibitors, addressing historically